Welcome to our dedicated page for Rocket Pharmaceu news (Ticker: RCKT), a resource for investors and traders seeking the latest updates and insights on Rocket Pharmaceu stock.
Rocket Pharmaceuticals, Inc. reports developments in rare-disease genetic medicines, including its commercial-stage therapy KRESLADI for pediatric patients with severe leukocyte adhesion deficiency-I and its broader pipeline of investigational gene therapies. Company updates commonly address FDA actions, clinical-program progress, regulatory submissions, and financial results tied to research, development, and commercial readiness.
Recurring news themes include the AAV cardiovascular portfolio, such as RP-A501 for Danon disease, RP-A601 for PKP2-arrhythmogenic cardiomyopathy, and RP-A701 for BAG3-related dilated cardiomyopathy. Rocket also reports capital and balance-sheet actions, including monetization of its Rare Pediatric Disease Priority Review Voucher, as well as presentations at healthcare conferences.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) reported a net loss of $43M, or $0.67 per share, for Q1 2022. The company holds $346.6M in cash, extending its operational runway into H1 2024. Key updates include the advancement of four clinical programs targeting Danon Disease, Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency, with data readouts expected throughout 2022. Significant leadership appointments were made, including Fady Malik, M.D., to the Board and Carlos Martin as Chief Commercial Officer. The company also anticipates AAV cGMP manufacturing readiness in Q2 2022.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is set to present at the Bank of America Securities Healthcare Conference on May 11 at 2:20 p.m. ET. The company specializes in developing genetic therapies for rare childhood disorders, including Fanconi Anemia and Danon Disease. Rocket utilizes a platform-agnostic approach, focusing on tailored therapy solutions. Given the ongoing impact of COVID-19, the company emphasizes the safety and effectiveness of its product candidates, while also addressing potential delays in clinical trials.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announces key upcoming presentations: President Kinnari Patel will present at the Guggenheim 3rd Annual Genomic Medicines and Rare Disease Conference on April 1 at 8:00 a.m. ET, and CEO Gaurav Shah will speak at the 21st Annual Needham Virtual Healthcare Conference on April 11 at 10:15 a.m. ET. The live webcasts will be accessible on the company's website, with replays available post-event. Rocket focuses on genetic therapies for rare childhood disorders, including Fanconi Anemia and Danon Disease.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has appointed Fady Malik, M.D., Ph.D., to its Board of Directors. Dr. Malik, with nearly 25 years of experience as a cardiovascular physician-scientist and biopharmaceutical executive, will serve as an independent non-executive director. CEO Gaurav Shah emphasized Dr. Malik's expertise in R&D and leadership in bringing medicines from research to clinical application, particularly in cardiology. Rocket is advancing its clinical pipeline for rare childhood disorders, including Danon Disease, and aims for agency alignment on its Phase 2 clinical study.
Rocket Pharmaceuticals (NASDAQ: RCKT) has appointed Jessie Yeung as Vice President of Investor Relations and Corporate Finance. With over 15 years of experience, including a previous role at Legend Biotech (NASDAQ: LEGN), Yeung will lead investor relations and capital market strategies. CEO Gaurav Shah emphasized Yeung's expertise will enhance communication with investors as the company approaches significant milestones in gene therapy clinical programs.
Rocket Pharmaceuticals, focusing on genetic therapies for rare childhood disorders, announced positive Phase 1 results for Danon Disease, showing clinical benefits in four adults. The data indicated sustained improvement across clinical metrics. In pivotal Phase 2 trials for LAD-I, nine patients exhibited successful engraftment, with CD18 expression ranging from 26% to 87%. Six out of eight patients in the Fanconi Anemia trial demonstrated engraftment, with data expected soon. The company holds a strong cash position of $388.7 million, ensuring operational funding into the second half of 2023.
Rocket Pharmaceuticals (NASDAQ: RCKT), a clinical-stage company focused on genetic therapies for rare childhood disorders, has announced that CEO Gaurav Shah will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 10 a.m. ET. Investors can access a live audio webcast of the presentation on the company's website. Rocket's pipeline includes therapies for conditions such as Fanconi Anemia and Danon Disease, utilizing both lentiviral and adeno-associated viral vector approaches.
Rocket Pharmaceuticals (NASDAQ: RCKT) announced key milestones for 2022 during the J.P. Morgan Healthcare Conference. Pivotal data from the LAD-I and Fanconi Anemia trials will be reported in Q2 and Q3, respectively. AAV GMP manufacturing in Cranbury, NJ is expected to begin in Q2, and data from Danon Disease pediatric cohorts is anticipated in Q3. Additionally, the initiation of pivotal Phase 2 trials for Danon Disease and PKD is planned for Q4, reflecting significant progress in advancing their genetic therapies for rare childhood disorders.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has announced that CEO Gaurav Shah, M.D. will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 10 at 1:30 p.m. ET. The event will be available for live audio streaming on the company’s website, with a replay accessible afterward. The company is focused on developing genetic therapies for rare childhood disorders, including Fanconi Anemia and Danon Disease, utilizing both lentiviral vector and adeno-associated virus-based therapies.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) reported positive updates from its Phase 2 trials for Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), and a Phase 1 trial for Pyruvate Kinase Deficiency (PKD) at the ASH Annual Meeting. Six of eight FA patients showed evidence of engraftment and improved bone marrow mitomycin C resistance. All eight LAD-I patients exhibited durable CD18 expression crucial for survival. Additionally, two PKD patients achieved sustained normal hemoglobin levels post-treatment. A webcast event is scheduled for December 14, 2021, to discuss these findings further.